Table 4.
Studies | Number of Patients | Number of PAL | Number of Positive PAL | Se (%) | Sp (%) | PPV (%) | NPV (%) |
---|---|---|---|---|---|---|---|
Chao et al., 2006 [12] | 49 | NR | 13 | 85 | 95 | 84.6 | 95.2 |
Suzuki et al., 2007 [13] | 30 | 19 | 1 | 0 | 100 | 0 | 94.7 |
Kitajima et al., 2008 [14] | 40 | 34 | NR | 51.7 | 99.4 | 83.3 | 97.3 |
Park et al., 2008 [15] | 53 | 31 | 7 | 57.1 | 87.5 | 57.1 | 87.5 |
Suga et al., 2011 [16] | 30 | 15 | 4 | 100 | 100 | 100 | 100 |
Crivellaro et al., 2013 [17] | 76 | 15 | 6 | 85.7 | 96 | 87.5 | 96.3 |
Gholkar et al., 2014 [18] | 20 | 13 | 1 | 100 | 66.7 | 20 | 100 |
Mayoral et al., 2016 [19] | 13 | 12 | 3 | 33 | 88.9 | 50 | 80 |
Atri et al., 2017 [20] | 215 | 160 | 23 | 65 | 88.0 | 48.4 | 93.8 |
Park et al., 2017 [21] | 362 | 118 | 11 | 18.2 | 98.1 | 92.1 | 50 |
Legros et al., 2019 [9] | 81 | 35 | 14 | 50 | 100 | 100 | 75 |
Our study | 200 | 200 | 55 | 61.8 | 89.7 | 69.4 | 86.1 |